English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

As judged by widespread utility in protein production from recombinant Escherichia coli and by the magnitude of royalty payments to Melbourne's Walter & Eliza Hall Institute (WEHI), the expression vector pGEX, invented by Dr Donald Smith, has been a significant commercial success. It is based on the 26kDa glutathione S-transferase of Schisto- soma japonicum (Philippines) termed Sj26GST, that emerged from work throughout the 1980's on resistance to infection in a peculiar mouse strain, WEHI 129/J. Sj26GST was the lead vaccine candidate for this human helminth worm being pursued in a long-term collaboration between WEHI in Australia and Dr Edito Garcia's 1 group at the College of Public Health, University of the Philippines in Manila that commenced in 1980. The product, pGEX, is an excellent example of commercial spin-off from basic research in mouse model systems that in- deed evolved into an applied research program but with a very different goal, namely rational molecular vaccine devel- opment.

The S. japonicum-Based pGEX Vector: Commercial Outcomes from Analysis of Model Host-Parasite Relationships in a “North-South” Collaboration